Pharming Group (PHGUF) to Release Earnings on Thursday

Pharming Group (OTCMKTS:PHGUF) is expected to be releasing its resultson Thursday, July 30th. Analysts expect the company to announce earnings of $0.0063 per share and revenue of $99.5160 million for the quarter.

Pharming Group (OTCMKTS:PHGUF) last posted its quarterly earnings data on Thursday, May 7th. The biotechnology company reported ($0.01) earnings per share for the quarter. The business had revenue of $72.45 million during the quarter, compared to analysts’ expectations of $92.06 million. Pharming Group had a return on equity of 4.64% and a net margin of 3.30%.

Pharming Group Price Performance

Shares of OTCMKTS:PHGUF opened at $1.30 on Wednesday. Pharming Group has a 1 year low of $1.14 and a 1 year high of $2.17. The company has a market capitalization of $872.39 million, a PE ratio of 65.03 and a beta of 0.47. The business has a fifty day moving average price of $1.24 and a two-hundred day moving average price of $1.51. The company has a debt-to-equity ratio of 0.40, a current ratio of 2.63 and a quick ratio of 2.06.

Pharming Group Company Profile

Pharming Group NV is a Netherlands-based biopharmaceutical company specializing in the development and commercialization of protein replacement therapies for rare diseases. Founded in 1988 and headquartered in Leiden, the company leverages transgenic technology to produce recombinant proteins, with its flagship product RUCONEST (recombinant C1 esterase inhibitor) indicated for the treatment of acute hereditary angioedema (HAE) attacks. RUCONEST is approved and marketed in the United States, Europe and several other territories through partnerships with leading specialty pharmaceutical companies.

Beyond RUCONEST, Pharming maintains a diversified pipeline targeting unmet needs in rare and ultra-rare disorders.